The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...

Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The ...

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Bristol Myers Squibb aims to generate around $1.5 billion in savings through 2025—a goal that it hopes to reach by lowering ...

The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...